Lung Cancer

Aflibercept combined with topotecan achieved slightly higher rates of PFS and disease control in patients with platinum-refractory, extensive-stage small cell lung cancer, compared with topotecan alone.

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.

New study reveals that widespread molecular screening of non–small cell lung cancer is feasible and can be performed outside of large academic medical centers.

The administration of nab-paclitaxel plus carboplatin results in a significantly higher ORR than conventional solvent-based paclitaxel with carboplatin in previously untreated patients with advanced NSCLC.

Three medical societies have joined in endorsing low-dose computed tomography screening for patients at high risk of developing lung cancer.

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Roman Perez-Soler, from the Montefiore Medical Center, on the Correlation Between Erlotinib-Induced Skin Rash and Overall Survival

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.

The addition of bevacizumab to first-line carboplatin-paclitaxel did not prolong survival in Medicare recipients with advanced non–small cell lung cancer.

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

The addition of thalidomide to chemoradiotherapy provides no survival benefit and increases toxicity in patients with unresectable stage III non-small cell lung cancer.

Dr. Elizabeth Gore, from the Medical College of Wisconsin, on Toxicity in Elderly Lung Cancer Patients

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.